ENFN vs. BASE, PDFS, OPRA, SOUN, MOMO, VTEX, DCBO, ZUO, EVBG, and TUYA
Should you be buying Enfusion stock or one of its competitors? The main competitors of Enfusion include Couchbase (BASE), PDF Solutions (PDFS), Opera (OPRA), SoundHound AI (SOUN), Hello Group (MOMO), VTEX (VTEX), Docebo (DCBO), Zuora (ZUO), Everbridge (EVBG), and Tuya (TUYA). These companies are all part of the "prepackaged software" industry.
Enfusion (NYSE:ENFN) and Couchbase (NASDAQ:BASE) are both small-cap computer and technology companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations, community ranking and institutional ownership.
In the previous week, Couchbase had 2 more articles in the media than Enfusion. MarketBeat recorded 2 mentions for Couchbase and 0 mentions for Enfusion. Enfusion's average media sentiment score of 0.00 beat Couchbase's score of -0.11 indicating that Enfusion is being referred to more favorably in the media.
Enfusion has a net margin of 3.45% compared to Couchbase's net margin of -44.54%. Enfusion's return on equity of 10.30% beat Couchbase's return on equity.
Enfusion currently has a consensus price target of $9.33, suggesting a potential downside of 0.39%. Couchbase has a consensus price target of $32.40, suggesting a potential upside of 32.35%. Given Couchbase's stronger consensus rating and higher possible upside, analysts clearly believe Couchbase is more favorable than Enfusion.
Enfusion has higher earnings, but lower revenue than Couchbase. Couchbase is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.
81.1% of Enfusion shares are owned by institutional investors. Comparatively, 96.1% of Couchbase shares are owned by institutional investors. 39.2% of Enfusion shares are owned by insiders. Comparatively, 22.5% of Couchbase shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Couchbase received 39 more outperform votes than Enfusion when rated by MarketBeat users. Likewise, 46.53% of users gave Couchbase an outperform vote while only 17.02% of users gave Enfusion an outperform vote.
Enfusion has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Couchbase has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.
Summary
Enfusion beats Couchbase on 10 of the 18 factors compared between the two stocks.
Get Enfusion News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENFN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENFN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enfusion Competitors List
Related Companies and Tools
